# A Study of ST-1898 for Unresectable or Metastatic Melanoma

Source: https://onco.cc/trials/nct06359860/  
OnCo record `nct06359860` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ST-1898 tablets in melanoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, now recruiting.

## Summary

A Study of ST-1898 for Unresectable or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06359860 by Beijing Scitech-Mq Pharmaceuticals Limited, with 64 participants planned, started 2023-11-07 and due to reach its primary completion in 2026-12. Interventions recorded: ST-1898 tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06359860
- Phase: 1/2
- Setting: A Phase Ib/II Study to Evaluate the Efficacy and Safety of ST-1898 in Subjects With Unresectable or Metastatic Melanoma
- Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT06359860: https://clinicaltrials.gov/study/NCT06359860

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Beijing Scitech-Mq Pharmaceuticals](https://onco.cc/companies/beijing-scitech-mq-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06359860.json